Show Me The Money

June 17, 2021 from 12:30 to 15:00
Hybrid @PLNT, Langegracht 70, 2312 NV Leiden
Logo

Hard money edition

Do you need funding for your startup? Interested in investor money?
Curious to see if sharing your company for cash, expertise and network is something for you?

Then come to our 1:1 sessions and find out what VCs, regional and corporate investors can do for your project. Learn about investor’s ticket sizes, funds, development stage sweetspots, regional, disease or tech preferences and whether they want to lead or follow. We offer you the chance to connect with investors interested in LSH startups. 

Download here the Show Me The Money Poster

Registion is closed. If you still want to join this event please send an e-mail to: events@lbsp.nl 

Powered by:

Participating investors

In alphabetical order

Bioqube

Bioqube Ventures is a specialist life sciences investment firm. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors. Contact: Alexander Demoulin

FARE

FARE Capital invests in the real economy on behalf of institutional investors. FARE is a real economy investment manager, bringing together the need for funding and the demand for attractive investing opportunities. We have established two distinctive funds: The SME Benchmark Fund is a loan fund, that is capable of disbursing loans to established enterprises. The FARE Capital Impact Fund aims to invest in starting enterprises in the area of Food and Health. Contact: Matthijs Snijder

FIRST / BioGeneration Ventures

We are a venture capital firm specialised in seed investment for innovative early stage companies. FIRST is a pre-seed fund that finances pioneering scientists in The Netherlands active in the emerging fields of regenerative medicine and cardiovascular diseases. BGV supports the FIRST fund as registered fund manager, making available its network, expertise and facilities. Contact: Rianne Ellenbroek

Innovation Industries

Innovation Industries is a leading Dutch independent venture capital investment firm, which has over € 260 million capital under management. We invest in Dutch 'deep tech' (i.e. HighTech, MedTech and Agri- & FoodTech) businesses with innovative proprietary scientific and engineering technology, solving real-world problems in identifiable markets. We have a multi stage investment approach and can invest up to € 25 million per company. Contact: Margherita Marchetti

Libertatis Ergo Holding

Libertatis Ergo Holding B.V. (LEH) is an independent legal entity that holds associate companies arising from Leiden University’s activities. LEH is also involved in several funds aimed at developing companies. All the shares in LEH are owned by Leiden University. The Executive Board acts as the shareholder. Contact: Rob Mayfield

LSP

LSP is one of the largest European investment firms providing financing for life sciences and health care companies. LSP’s management has raised over €2 billion ($2.5 billion) and supported the growth of 300 companies since it started to invest in 1988, including signature deals such as argenx, Crucell and Neuravi. With offices in Amsterdam, Munich and Boston, LSP currently has the possibility to invest through five strategies, each having a distinctive investment scope and a dedicated team: LSP 6 invests in private early- to late-stage drug development and medical technology companies; LSP HEF 2 focuses on private late-stage medical technology companies; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; LSP Public targets public healthcare companies; and EBAC is the first healthcare SPAC to exclusively focus on European biotech. LSP is an active contributor to the global life sciences industry and the European life science eco-system by assuming for-profit and not-for-profit roles as initiators, founders and board members in various private and public bodies and organizations, for example being founder and board member of the Oncode Institute. Contact: Sonia Hallen

Meneldor

Meneldor focuses on early stage biotech and pharma companies that (re)develop (New) Biological or Chemical Molecular Entities, that have outstanding technology with strong IP, address significant unmet medical needs and attractive markets. We are especially scouting for companies that work on relatively low risk and high growth opportunities. We mainly invest in projects which are in preclinical, Phase I or Phase II and in indications with preferably clear well defined clinical endpoints. Our geographic focus is Western Europe. Contact: Frans van Dalen

NextGen

NextGen Ventures invests in knowledge-intensive companies that drive change within the healthcare industry, preferably potential breakthrough innovations that are past the idea stage and working towards a market position. The fund prefers to take a significant minority stake in companies with strong management. Contact: Roel Dekkers

Scarabee

Scarabee is the investment pool of a network of informal investors. Next to investing capital in innovative start-ups and scale-ups we bring our extensive experience in deal making, finance/investment, strategy, operations and HR on board. Our team has a deep reaching understanding of the biotech/life sciences, SaaS and energy sectors. With a preference for B2B settings the founder team, the business case and the current financing situation will determine our interest in a case. Contact: Ronald Loggers

Starfish Innovations

Starfish Innovations is an investment fund and commercialization hub that seeks to accelerate breakthroughs in regenerative medicine. Founded in 2016 by the Leiden University Medical Centre (LUMC), we have been able to build a strong early-stage pipeline of regenerative medicine technologies through our direct access to the promising science at LUMC as well as our global network of academic institutions and industry alike. Contact: Chris Tieken

Thuja

Thuja manages several venture capital funds aimed at building and scaling companies in the fields of (bio)pharmaceuticals, MedTech and digital health. In addition to generating a financial return for its investors, Thuja’s investments positively impact the health and well-being of patients. Thuja serves physicians and patients worldwide by providing capital to daring entrepreneurs with ground-breaking product concepts locally. Thuja’s investment team consists of seasoned investors and entrepreneurs with a proven track record. Consistently performing in the top quartile, the team has backed and helped to build several of today’s unicorns, as a first investor in Galapagos, Argenx and Nightbalance. Contact: Lisanne Blauw

UNIIQ & IQ capital

UNIIQ: A € 22 million investment fund focused on the proof-of-concept phase, UNIIQ helps entrepreneurs in West Holland bring their unique innovations to market faster. UNIIQ offers enterprising companies seed capital to realise their plans and bridge the riskiest phase from concept to promising business. IQ Capital: A fund of € 80 million for investments in innovative companies, from startup to scale-up and mature SMEs in West Holland. UNIIQ Contact: Thijs van den Munckhof. IQ Capital Contact: Gerty Holla

V-Bio

We are a life sciences Venture Capital fund that helps transform scientific innovation into products that positively impact people’s lives. We focus on therapeutics, diagnostics supporting medical therapies, and sustainable agriculture. Additional to our preferred relationship with the Belgium-based VIB we source deals coming from any research institute, entrepreneurial initiative, or spin-outs from mature companies with a geographical focus on Europe. Contact: Shelley Margetson

Associated investors

INKEF

We are a life sciences Venture Capital fund that helps transform scientific innovation into products that positively impact people’s lives. We focus on therapeutics, diagnostics supporting medical therapies, and sustainable agriculture. Additional to our preferred relationship with the Belgium-based VIB we source deals coming from any research institute, entrepreneurial initiative, or spin-outs from mature companies with a geographical focus on Europe. Contact: Thijs Cohen Tervaert

Did you know? We have now 19,900 jobs, in 2025 we are expecting 25,000 jobs